LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Status Terminated

Clinical Trial Summary

This will be a single arm Phase II study.

Clinical Trial Description

LBH589 (20 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00594230
Study type	Interventional
Source	SCRI Development Innovations, LLC
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2008
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02550535` - A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients	Phase 1/Phase 2
Completed	`NCT00186342` - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies	N/A
Completed	`NCT00528983` - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia	Phase 1
Completed	`NCT01355913` - Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Withdrawn	`NCT04985656` - A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes	Phase 2
Completed	`NCT01736683` - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)	Phase 2
Completed	`NCT02333058` - Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies	Phase 2
Completed	`NCT01135849` - B-Receptor Signaling in Cardiomyopathy	N/A
Withdrawn	`NCT04395092` - Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)	Phase 2
Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
Recruiting	`NCT05092451` - Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances	Phase 1/Phase 2
Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
Completed	`NCT02390414` - The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Completed	`NCT01326377` - ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)	Phase 2
Completed	`NCT02966782` - A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)	Phase 1
Recruiting	`NCT02779569` - A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)	N/A
Recruiting	`NCT02099669` - Red Blood Cell Transfusion Thresholds and QOL in MDS	N/A
Completed	`NCT01392989` - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders	Phase 2
Not yet recruiting	`NCT06398457` - Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies	Early Phase 1
Recruiting	`NCT02775383` - The National Myelodysplastic Syndromes (MDS) Study